Where Freya Pharma Solutions itself has been a promising pharmaceutical company expert in innovative therapies for women suffering from Female Sexual Disorders (FSD), its rebrand announcement is the same, promising, with a level-up. The Freya Phar, a solutions has been renamed to Arletta Pharma Solutions from today onwards. This new name is inspired by a rare and unique butterfly species that dramatically represents the company’s transformation as it succeeds in achieving the crucial clinical milestones and its intelligent strategic objectives of confirming regulatory approval.
The Chief Executive Officer and CEO of Arletta Pharma Solutions, Nicole Hijnen, said, “Just like a caterpillar blooming (transforming) into a butterfly, this rebranding also marks the start of our final phase. This name change idea came at the optimal moment in our progression as we modernise our clinical programs and are all set to serve on our focused mission to identify a meaningful unmet medical need that has been adversely impacting the infinite set of women population globally.”
As Arletta is closely related to the rare butterfly species, it holds the thoughtful significance for women’s medical care. Here, the butterfly represents beauty, freedom, change and transformation; these concepts largely and deeply connect across women’s healthcare. The term ‘butterfly’ is mostly used in a medical context, internationally, which is based on women’s health, such as diagnostic indicators, anatomical structures, that dramatically mirror the transitional nature of women’s unique and valuable life stages.
Women experience commendable transformations like perimenopause, postmenopause, puberty, and reproductive years, among which every transformation symbolises a metamorphosis that needs a special medical understanding and attention. Arletta Pharma’s key aim is to establish innovative therapies for Female Sexual Interest/Arousal Disorder (FSIAD) that accept and promote rightfully these commendable transformations and the need for main therapeutic solutions that respect and consider the complications of female sexual health.
Whereas, the Arletta Pharma’s Clitoral Duplex Ultrasonography (CDU) Phase 2 study is in progress at Chaim Sheba Medical Center. The study is examining the two testosterone-sildenafil dose combinations in around 16 premenopausal women having generalised FSIAD. This study is under the supervision of Dr Anna Padoa and Prof. Cobi Reisman.
This study uses the clitoral Doppler duplex ultrasound imaging to collectively analyse the clitoral blood flow parameters along with the preliminary data that is expected to be declared in the near term. Further, the expansion and other initiatives are bolstering rebranding and additional developments in the vast healthcare sector.
Holding M.Pharm in Pharmaceutical Chemistry, Chandni crafts cutting-edge, research-driven healthcare news for Towards Healthcare, combining scientific depth with innovative storytelling to simplify complex topics for global readers.
